# ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma

Source: https://onco.cc/trials/nct03897543/  
OnCo record `nct03897543` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ABX196 in hepatocellular carcinoma, run by Abivax S.A., now recruiting.

## Summary

ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma is a phase 1/2 interventional study registered as NCT03897543 by Abivax S.A., with 48 participants planned, started 2019-08-30 and due to reach its primary completion in 2021-06-30. Interventions recorded: ABX196.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03897543
- Phase: 1/2
- Setting: A Phase 1-2 Study of ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
- Sponsor: Abivax S.A.
- Enrolled: 48

## Sources

- ClinicalTrials.gov NCT03897543: https://clinicaltrials.gov/study/NCT03897543

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)

---
JSON: https://onco.cc/api/v1/entities/nct03897543.json